Who We Fund
Investments in Industry
We are working with Novartis, Henry Ford Hospital, and Columbia University to develop state-of-the-art model systems to id
- Exosome Diagnostics
ABC2 and Exosome Diagnostics are collaborating with two leading academic research centers to accelerate the clinical validation of Exosome Diagnostic's biofluid-based diagnostic technology.
ABC2’s investment provided the support Agios needed to move its cancer metabolism project into brain cancer. Prior to our involvement, Agios focused exclusively on leukemia research.
ABC2 funded Genentech’s early stage research and clinical trial work to test and develop the drug Avastin to treat brain cancer patients.
- Regulus Therapeutics
Regulus is now working with Samsung Medical Center to develop a microRNA therapeutic to target the “master control switches” in brain tumors.
ABC2 was the first non-profit organization to fund Tocagen, a biotech company that was able to then go onto raise additional funding for their groundbreaking therapy.
Brain Tumor Research Grants
- Johns Hopkins
We are funding a clinical trial at Johns Hopkins to test whether mebendazole, a drug already approved by the FDA to fight
- UCSD & Regulus
Early detection of tumor recurrence remains one of the greatest challenges in the treatment of brain cancer.
- Split Immunity Research
We're funding the innovative work by researchers at Tel Aviv Sourasky Medical Center.
We are funding a UCSF project to understand the effects of temozolomide on low-grade gliomas.
- FCBTR/ABC2 Grants
Together, since 2010, FCBTR and ABC2 have together funded more than $925,000 in Florida-based brain tumor research
- Duke Medicine
Duke Medicine and Accelerate Brain Cancer Cure have worked together to advance treatments since 2001. We've funded 25 different projects by Duke investigators.
Our investment and scientific guidance is helping to advance the work of an international consortium working on a treatment for a rare pediatric brain tumor called diffuse intrinsic pontine glioma (DIPG).
We are funding whole exome sequencing of brain tumors at the Broad Institute to advance research at Dana-Farber on the personalized NeoVax immunotherapy treatment.
We are funding the development of a clinical trial to determine if retinoic acid -- Accutane -- might be an effective brain cancer treatment for patients with IDH gene mutations.
- Mayo Clinic / T-Gen
ABC2’s investment helps move forward a novel personalized medicine trial for glioblastoma patients led by Mayo Clinic, one of the leading clinical centers, and TGen, a cutting edge genomics lab.